Ranbaxy Laboratories, Inc.

Ranbaxy Laboratory Limited

Yatendra Kumar

Mohan Prasad

Jag Mohan Khanna

Rajesh Kumar Thaper

Mahavir Singh Khanna

Ram Chander Aryan

Neera Tewari

Rakesh Kumar Arora

S M Kumar

Bishwa Prakash Rai

Kaptan Singh

Anita Chugh

Satyananda Misra

Kumar Hari Bhushan

Swargam Sathyanarayana

Mohammad Salman

Jitendra Anant Sattigeri

Shailendra Kumar Singh

Neera Tiwari

Saridi Madhava Dileep Kumar

Seema Ahuja

Shantanu De

Arun Malhotra

Radhakrishnan Gowri Shankar

Naresh Kumar

Pankaj Sharma

Chandra Has Khanduri

Kiran Bala

Om Dutt Tyagi

Hashim Nizar Poovanathil Nagoor Meeran

Purna Chandra Ray

Neela Praveen Kumar

Ramnik Sharma

Bakthavathsalan Vijayaraghavan

Nitin Maheshwari

Jayachandra Suresh Babu

Ran Chander Aryan

Azok Nath

Rajest Kumar Thaper

Sm Dileep Kumar

Vikram Krishna Ramanathan

Praveen Kumar Neela

Shallendra Kumar Singh

S M Dileep Kumar

Mohammad Rafeeq

Mashkoor Husain

Gowri Shankar

Mahivir Singh Khanna

Bhargav R Panyda

Vikram Krishna Ramanthan

Jitendra Sattiegeri

SM Dileep S-Block 122 1St Fl South Ave Kumar

Hashim NPN Uzhijethu House Meeran

The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.

Barium salt of benzimidazole derivative

The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)--methoxy--[[(-methoxy--dimethyl--pyridinyl)-methyl]sulfinyl]-H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.

The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia.

Process for the preparation of ziprasidone

A process for the production of amorphous atorvastatin calcium and stabilized, amorphous atorvastatin calcium is provided.

Process for the production of atorvastatin calcium in amorphous form

The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Substituted pyrrole derivatives and their use as HMG-CO inhibitors

The present invention relates to a process for enantioselective synthesis of substituted pyridinylmethyl sulfinyl-benzimidazole of compound of Formula (I). The process includes enantioselective catalytic oxidation of a substituted pyridinylmethyl prochiral sulfide derivative of compound of Formula (II) with an oxidizing agent in the presence of a chiral transition metal complex and a base in the absence of an organic solvent. 

Processes for the preparation of substituted sulfoxides

The present invention relates to a process for the preparation of rosuvastatin calcium, a promising new HMG-CoA reductase inhibitor.

Process for the preparation of rosuvastatin

The invention relates to an amorphous form of the salts of the (-) enantiomer or (S)-enantiomer of omeprazole, i.e., esomeprazole. The invention also relates to processes for preparing amorphous esomeprazole salts and pharmaceutical compositions that include the amorphous esomeprazole salts.

Amorphous form of esomeprazole salts

The present invention relates to an improved process for the preparation of imipenem comprising reacting a bicyclo ketone precursor of the Formula II, wherein R is a protecting group, with a phosphorohalidate in the presence of a base and a catalytic amount of dialkylaminopyridine.

Process for the preparation of imipenem

The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity, which comprises dissolving crude imipenerm in warm water to which some base has been added to obtain a solution, subjecting the resultant solution to activated carbon treatment, and adding an organic solvent to precipitate imipienem monohydrate as a crystalline product.

Process for the preparation of crystalline imipenem

The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity comprising the steps of treating an aqueous solution containing imipenem with an organic solvent, wherein the imipenem is not lyophilized; and isolating the pure crystalline imipenem monohydrate from the reaction mixture thereof.

Process for the isolation of crystalline imipenem

The present invention relates to a cost effective and industrially useful process for the preparation of substantially pure acitretin. More specifically, the present invention relates to the preparation of acitretin of high purity and yield.

Process for the preparation of acitretin

The optically active compound, R (&#x2212;)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide in good optical purity, a metabolite of the &#x3b1;-adrenergic blocking agent tamsulosin, and methods for the preparation thereof. Pharmaceutical compositions including the optically active compound and methods of treatment comprising administration of an effective &#x3b1;-adrenergic antagonistic amount of such compositions to mammals.

Tamsulosin derivative

The invention relates to particular hydroxyl and protected hydroxyl derivatives of compounds known to be useful as HMG CoA-reductase inhibitors. In particular, herein are provided hydroxyl and protected hydroxyl compounds of Formula I and their corresponding lactones.

HMG CoA-reductase inhibitors

Growing community of inventors

Haryana, India

Yatendra Kumar